Community Bank N.A. boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 6.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,693 shares of the biopharmaceutical company’s stock after acquiring an additional 2,247 shares during the quarter. Community Bank N.A.’s holdings in Bristol-Myers Squibb were worth $2,309,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. Advisor Partners LLC raised its holdings in Bristol-Myers Squibb by 6.9% during the 3rd quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock worth $2,356,000 after buying an additional 2,382 shares during the period. Oppenheimer & Co. Inc. grew its stake in Bristol-Myers Squibb by 2.5% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock valued at $19,976,000 after acquiring an additional 8,813 shares in the last quarter. Israel Discount Bank of New York grew its stake in Bristol-Myers Squibb by 31.8% during the 2nd quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock valued at $586,000 after acquiring an additional 2,540 shares in the last quarter. Van ECK Associates Corp grew its stake in shares of Bristol-Myers Squibb by 0.7% in the 3rd quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock valued at $50,436,000 after buying an additional 5,451 shares in the last quarter. Finally, Aperio Group LLC grew its stake in shares of Bristol-Myers Squibb by 12.7% in the 3rd quarter. Aperio Group LLC now owns 854,457 shares of the biopharmaceutical company’s stock valued at $54,463,000 after buying an additional 96,561 shares in the last quarter. Hedge funds and other institutional investors own 71.55% of the company’s stock.
In related news, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction on Friday, December 15th. The shares were purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $66.68 on Wednesday. Bristol-Myers Squibb Co has a 1 year low of $51.56 and a 1 year high of $70.05. The firm has a market capitalization of $110,117.72, a price-to-earnings ratio of 113.02, a price-to-earnings-growth ratio of 2.07 and a beta of 0.98. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the prior year, the business posted $0.63 earnings per share. The business’s revenue was up 3.9% compared to the same quarter last year. equities research analysts anticipate that Bristol-Myers Squibb Co will post 3.2 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 271.19%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.